We are live on ! Find out more
AXDX

Accelerate Diagnostics

Delisted

AXDX was delisted on the 14th of May, 2025.

38 hedge funds and large institutions have $14.7M invested in Accelerate Diagnostics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less capital invested

Capital invested by funds: $18M → $14.7M (-$3.33M)

24% less funds holding

Funds holding: 5038 (-12)

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

Holders
38
Holders Change
-12
Holders Change %
-24%
% of All Funds
0.6%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
6
Reduced
12
Closed
19
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
+$14K
Name Holding Trade Value Shares
Change
Change in
Stake
Stifel Financial
51
Stifel Financial
Missouri
-$8.1K -1,000 Closed
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
-$2.51K -310 Closed
Group One Trading
53
Group One Trading
Illinois
-$1.66K -246 Closed
Osaic Holdings
54
Osaic Holdings
Arizona
-$1.41K -173 Closed
Simplex Trading
55
Simplex Trading
Illinois
-$1K -124 Closed
BF
56
BOK Financial
Oklahoma
-$810 -100 Closed
PNC Financial Services Group
57
PNC Financial Services Group
Pennsylvania
-$162 -20 Closed

AXDX Hedge Fund Activity: Q3 2023 in Review

38 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2023, worth a combined $14.7M — down 18% from $18M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of AXDX and 9 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Cannell & Co, opening a new position worth an estimated $772K. The largest seller was Millennium Management, exiting entirely with an estimated $99.7K sold.

  • 38 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2023, down from 50 in Q2 2023.
  • Funds reported $14.7M of Accelerate Diagnostics stock for Q3 2023, down 18% quarter-over-quarter.
  • 9 funds opened new Accelerate Diagnostics positions in Q3 2023 and 19 closed out, a net change of -10 holders.
  • The largest Accelerate Diagnostics buyer in Q3 2023 was Cannell & Co, an estimated $772K added.
  • The largest Accelerate Diagnostics seller in Q3 2023 was Millennium Management, an estimated $99.7K sold.

Based on aggregated 13F filings for Q3 2023.